Top

Published in:

01-12-2019 | Case Report

Refractory Hypercalcemia in Squamous Cell Carcinoma of the Esophagus—a Case Report and Review of Literature

Authors: Hamza Arif, Moeezullah Beg, Sohaib Zahid, Moaz Sial, Aditya Talwar, Antonios Christou, Michael Babich

Published in: Journal of Gastrointestinal Cancer | Issue 4/2019

Excerpt

Hypercalcemia is a commonly encountered issue in malignancy, occurring in nearly 20 to 30% of patients at some point during their disease course [1]. Although malignancy, including squamous cell carcinomas (SCC), and primary hyperparathyroidism are most frequently associated with hypercalcemia other causes have also been identified [2]. Hypercalcemia of malignancy in solid tumors is a poor prognostic sign and nearly 50% of patients die within 30 days [3]. Lung and breast cancer are two of the most common causes of hypercalcemia in malignancy, but it has also been observed in esophageal cancer, with frequency of up to 21% [4]. …

Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.CrossRef

Jacobs TP, Bilezikian JP. Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005;90(11):6316–22.CrossRef

Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality: clinical experience in 126 treated patients. Ann Intern Med. 1990;112(7):499–504.CrossRef

Watanabe HA, Matsushita H, Matsui H, Komatsu T, Taguchi S, Sata H, et al. Esophageal carcinoma with high serum parathyroid hormone-related protein (PTHrP) level. J Gastroenterol. 1999;34(4):510–5.CrossRef

Jais P, Bouizar Z, Binn M, et al. Parathyroid hormone-related protein in an esophageal squamous cell carcinoma with tumor-induced hypercalcemia. Am J Gastroenterol. 1997;92(2):343–6.PubMed

Fernandez-Real JM, Villabona C, Soler J. Oesophageal carcinoma presenting as isolated malignant hypercalcaemia. Postgrad Med J. 1994;70(828):765–6.CrossRef

Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DSA. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab. 2015;100(5):2024–9.CrossRef

Geddes LG Jr, Dorn RA, Wadleigh RG. Hypercalcemia in patients with esophageal cancer. J Exp Clin Cancer Res. 1999;18(1):61–2.PubMed

Tachimori Y, Watanabe H, Kato H, Yamaguchi H, Nagasaki K, Honda S, et al. Hypercalcemia in patients with esophageal carcinoma. The pathophysiologic role of parathyroid hormone-related protein. Cancer. 1991;68(12):2625–9.CrossRef

10.

Skrabanek P, McPartlin J, Powell D. Tumor hypercalcemia and “ectopic hyperparathyroidism”. Medicine (Baltimore). 1980;59(4):262–82.CrossRef

11.

Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J. 1995;71(831):28–31.CrossRef

12.

Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab. 1993;76(5):1373–5.PubMed

13.

Lee JK, Chuang MJ, Lu CC, Hao LJ, Yang CY, Han TM, et al. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population. J Endocrinol Investig. 1997;20(7):404–9.CrossRef

14.

Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet. 1993;341(8861):1611–3.CrossRef

Title: Refractory Hypercalcemia in Squamous Cell Carcinoma of the Esophagus—a Case Report and Review of Literature
Authors: Hamza Arif
Moeezullah Beg
Sohaib Zahid
Moaz Sial
Aditya Talwar
Antonios Christou
Michael Babich
Publication date: 01-12-2019
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 4/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-018-0124-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database

Physical Activity and Sedentary Behavior in Older Gastrointestinal Cancer Survivors: Need and Acceptability of Digital Health Interventions

Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder

Emergency Laparoscopic Gastrectomy for Intraperitoneal Ruptured Gastric Gastrointestinal Stromal Tumor

Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran

A Rare Case of a Metastatic Gastrointestinal Stromal Tumor (GIST): a Case Report and Review of the Literature

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials